EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Vergleichsstudie

Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China

Wei Wang, Wei Zhang, Li-Ping Su, Li-Hong Liu, Yu-Huan Gao, Quan-Shun Wang, Hang Su, Yu-Qin Song, Hui-Lai Zhang, Jing Shen, Hong-Mei Jing, Shu-Ye Wang und 9 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05708-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Wei Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, 1, Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Aminopyridines, Benzamides, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, Chinese Academy of Medical Sciences Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this prospective, multicenter, Phase 2 clinical trial (NCT02987244), patients with peripheral T-cell lymphomas (PTCLs) who had responded to first-line chemotherapy with cyclophosphamide, doxorubicin or epirubicin, vincristine or vindesine, etoposide, and prednisone (Chi-CHOEP) were treated by autologous stem cell transplantation (ASCT) or with chidamide maintenance or observation. A total of 85 patients received one of the following interventions: ASCT (n = 15), chidamide maintenance (n = 44), and observation (n = 26). estimated 3 PFS and OS rates were 85.6%, 80.8%, and 49.4% (P = 0.001). The two-year OS rates were 85.6%, 80.8%, and 69.0% (P = 0.075).The ASCT and chidamide maintenance groups had significantly better progression-free survival (PFS) than the observation group (P = 0.001, and P = 0.01, respectively). The overall survival (OS) differed significantly between the chidamide maintenance group and the observation group ( P = 0.041). The multivariate and propensity score matching analyses for PFS revealed better outcomes in the subjects in the chidamide maintenance than observation groups (P = 0.02). The ASCT and chidamide maintenance groups had significant survival advantages over the observation group. In the post-remission stage of the untreated PTCL patients, single-agent chidamide maintenance demonstrated superior PFS and better OS than observation. Our findings highlight the potential benefit of chidamide in this patient subset, warranting further investigation through larger prospective trials. Clinical trial registration: clinicaltrial.gov, NCT02987244. Registered 8 December 2016, http://www.clinicaltrials.gov/ct2/show/NCT02987244 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralAminopyridinesBenzamidesHematopoietic Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAdultMiddle AgedProspective StudiesChinaTransplantation, AutologousAgedSurvival RateYoung AdultMaintenance ChemotherapyAutograftsRemission InductionAdolescent

Stichwörter der Autor:innen

Autologous stem cell transplantationChidamideChidamide maintenance therapyPeripheral T-cell lymphoma

Substanzen

AminopyridinesN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideBenzamides

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital, 1, Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China.
  • Department of Hematology, Peking Union Medical College Hospital, 1, Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China. vv1223@vip.sina.com.
  • Department of Hematology, Shanxi Provincial Cancer Hospital, 3 Worker's New Village, Xinghualing District, Taiyuan, Shanxi, China. Sulp2005@sohu.com.
  • Department of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Hematology, Chinese PLA General Hospital, Beijing, China.
  • Department of Lymphoma, The 307 Hospital of PLA, Beijing, China.

Förderung

  • the National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation
  • Chinese Academy of Medical Sciences Innovation Fund
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Wang, W., Zhang, W., Su, L. P., Liu, L. H., Gao, Y. H., Wang, Q. S., Su, H., Song, Y. Q., Zhang, H. L., Shen, J., Jing, H. M., Wang, S. Y., Cen, X. N., Liu, H., Liu, A. C., Li, Z. J., Luo, J. M., He, J. X., Wang, J. W., …, & Zhou, D. B. (2024). Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China. Annals of Hematology. https://doi.org/10.1007/s00277-024-05708-w

Vancouver

Wang W, Zhang W, Su LP, Liu LH, Gao YH, Wang QS, et al. Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China. Annals of Hematology. 2024. doi:10.1007/s00277-024-05708-w

BibTeX
@article{Wang2024,
  author = {Wang, Wei and Zhang, Wei and Su, Li-Ping and Liu, Li-Hong and Gao, Yu-Huan and Wang, Quan-Shun and Su, Hang and Song, Yu-Qin and Zhang, Hui-Lai and Shen, Jing and Jing, Hong-Mei and Wang, Shu-Ye and Cen, Xi-Nan and Liu, Hui and Liu, Ai-Chun and Li, Zeng-Jun and Luo, Jian-Min and He, Jian-Xia and Wang, Jing-Wen and O'Connor, O A and Zhou, Dao-Bin},
  title = {Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05708-w}
}
Kostenlos starten →